Cost-Effectiveness Analysis Saudi Arabia

SFDA cost-effectiveness analysis requirements in Saudi Arabia

SFDA published its Economic Evaluation Studies Guideline on 10 July 2024, followed by a Pharmacoeconomic Submission Portal Manual in January 2025, establishing the current framework for how cost-effectiveness evidence is reviewed as part of drug registration and pricing. General dossier requirements under this framework became mandatory in January 2025, and the economic evaluation component — including cost-effectiveness analysis where applicable — became mandatory from 1 July 2025. A cost-effectiveness analysis submitted today is read against a defined, current guideline rather than an informal or evolving expectation, which means model structure, comparator selection, and sensitivity reporting need to match what SFDA reviewers are specifically looking for rather than what a global submission template happens to produce.

SFDA's framework sorts economic evidence into two tiers. Budget impact analysis and cost-minimisation analysis are classified as "Partial Economic Studies" — the lighter evidence requirement. Cost-utility analysis (cost-effectiveness expressed as cost per quality-adjusted life year) and cost-benefit analysis are classified as "Full Economic Studies," the tier SFDA expects for products where comparative clinical effectiveness against standard of care is a material consideration — typically chronic-disease, oncology, and specialty therapies with a meaningfully different cost or outcome profile from existing alternatives. A submission scoped only around budget impact because it is the smaller deliverable risks discovering mid-review that the product's profile actually triggers the Full Economic Study tier, at which point rebuilding under committee deadline pressure is far more expensive than scoping both analyses together from the outset.

SFDA and NUPCO sit on either side of the pricing question, and a cost-effectiveness analysis has to speak to both without confusing their separate roles. SFDA sets the public list price and reviews the economic evaluation dossier at registration; NUPCO, the PIF-owned National Unified Procurement Company established in 2009, centralizes public-sector tendering and negotiates confidential net pricing through its own contracts, with the government tender market estimated at roughly SAR 21 billion. A cost-effectiveness analysis built to satisfy SFDA registration is not automatically the same document a NUPCO tender evaluator wants to see — SFDA reviews the clinical-value argument against the public list price, while NUPCO's technical committee weighs the economic evidence alongside volume commitments and net-pricing structure. BioNixus scopes which audience a given cost-effectiveness deliverable is actually being built for before model architecture is finalized, rather than assuming one document serves both purposes unchanged.

Health technology assessment in Saudi Arabia is best understood as a national HTA function operating within SFDA, with the country's formal HTA framework continuing to be formalized rather than fixed. Public documentation of the exact review body, its founding history, and its procedural timelines remains thinner than for long-established HTA agencies elsewhere, and BioNixus deliberately avoids asserting specifics that are not yet consistently published — sponsors should expect the HTA review pathway to keep evolving alongside SFDA's EES rollout, and a cost-effectiveness dossier built with that trajectory in mind ages better than one that assumes today's process is permanent.

Comparator selection for a Saudi cost-effectiveness analysis has to account for SFDA's reliance on external reference pricing, which draws on public list prices across roughly sixteen international markets to anchor the Saudi price. A cost-effectiveness analysis that ignores this reference-pricing context and argues value purely on local cost offsets can miss the pricing reality the model needs to justify — the comparator, its price, and the reference-pricing basket it sits within all have to be consistent with what SFDA's pricing procedure will actually apply.

Managed entry agreements — both financial arrangements (simple discounts, price-volume caps) and outcomes-based arrangements tied to a measurable clinical result — are a growing feature of Saudi pricing and reimbursement negotiations where cost-effectiveness uncertainty is a barrier to listing. A commonly cited example structures rebates around a hepatitis C treatment achieving a sustained virologic response threshold of 95% or higher, illustrating how an outcomes-based agreement can bridge a gap between a sponsor's claimed value and a payer's willingness to accept that value without further evidence. Where a cost-effectiveness analysis carries meaningful uncertainty in its base case, BioNixus scopes managed entry agreement design as a parallel workstream rather than treating the economic model and the risk-sharing structure as sequential, unrelated deliverables.

CBAHI — the Saudi Central Board for Accreditation of Healthcare Institutions, operating under the Saudi Health Council — is a healthcare quality and accreditation body, not an HTA, pricing, or reimbursement authority. It is a distinction worth stating plainly because the two functions are easy to conflate: CBAHI accreditation status can influence which facilities participate in certain NUPCO-tendered programs, but it plays no role in reviewing a cost-effectiveness dossier or setting a reimbursement decision. A cost-effectiveness submission strategy that assumes CBAHI has a pricing or HTA role has misread the institutional map.

Why cost-effectiveness thresholds in Saudi Arabia require careful framing

The GCC pharmaceutical market was worth roughly USD 23.7 billion in 2024 and is projected to reach about USD 49 billion by 2033 — a 7.6% CAGR (BioNixus market analysis, 2024). Saudi Arabia alone accounts for around USD 9.4 billion of 2024 spend, but UAE, Kuwait, and Qatar each follow distinct access and pricing logic.

Specialty and chronic-care portfolios drive much of the innovative volume; recruitment and sizing plans prioritize the facilities and networks where those patients are managed rather than treating the region as one homogeneous panel.

Saudi Arabia accounts for roughly USD 9.4 billion of the GCC's approximately USD 23.7 billion 2024 pharmaceutical spend, making it the market where a cost-effectiveness argument carries the most weight — and the most scrutiny — in the region. Vision 2030's Health Sector Transformation Program is the explicit policy rationale behind SFDA's move toward mandatory economic evaluation: the stated shift from volume-based to value-based healthcare financing is why cost-effectiveness evidence, not just clinical efficacy, is now a registration-stage requirement rather than an optional supporting exhibit.

Saudi Arabia has not published a single, officially codified cost-effectiveness threshold — no fixed willingness-to-pay figure that a submitted ICER is mechanically compared against. The most cited research-derived estimate places a plausible Saudi threshold in the range of approximately SAR 50,000 to 75,000 per QALY, equivalent to roughly 58% to 86% of GDP per capita, drawn from published health-economics literature rather than a government policy document. BioNixus treats this range as a useful analytical anchor for framing a value argument — not as a hard pass/fail line a committee applies automatically — because a formal, government-mandated threshold would need agreement across the Ministry of Health, Ministry of Finance, and wider policy stakeholders that has not yet been finalized and published as a single number.

Because no fixed threshold exists, the strength of a Saudi cost-effectiveness submission rests more heavily on the credibility of its inputs — locally sourced or locally validated data, transparent sensitivity analysis, and a comparator argument consistent with SFDA's reference-pricing framework — than on hitting a specific ICER target. A technically well-modeled ICER that a reviewer cannot trace back to defensible Saudi-relevant inputs is weaker evidence than a higher ICER built on data the reviewer can verify.

NUPCO's centralized tender scale — a government tender market of roughly SAR 21 billion — means a cost-effectiveness argument that supports a favorable NUPCO net-pricing negotiation has outsized commercial consequences relative to a comparable submission in a smaller GCC market, which is part of why Saudi Arabia is where BioNixus recommends sponsors invest the most rigor in local data sourcing rather than porting a regional or global model with minimal adaptation.

Explore the HEOR consulting Saudi Arabia for regional context and related services.

Cost-effectiveness analysis services BioNixus delivers in Saudi Arabia

Cost-effectiveness analysis methodology for Saudi Arabia submissions

A cost-effectiveness analysis evaluates whether the health benefit a new therapy delivers justifies its additional cost relative to the existing standard of care. The core output is the incremental cost-effectiveness ratio (ICER) — the additional cost divided by the additional health benefit, most commonly expressed as cost per quality-adjusted life year (QALY) gained. A QALY combines length of life and quality of life into a single measure: one QALY equals one year of life in full health, and a year lived in a health state valued at 0.7 on a standard utility scale contributes 0.7 QALYs. Utility values are typically derived from preference-based instruments such as the EQ-5D, ideally sourced from studies conducted in Arab or regional populations rather than transferred directly from UK or US tariffs, since preference-based health-state valuations can differ meaningfully across populations.

Model structure depends on the disease area and the shape of the available clinical evidence. Decision-tree models suit acute, short-duration conditions where patients move through a defined sequence of events over weeks to months. Markov cohort models — the most common structure for chronic-disease submissions — define a set of health states and model transitions between them over a lifetime or multi-year horizon, and are the standard approach for conditions like diabetes, cardiovascular disease, and many chronic respiratory or renal conditions. Partitioned survival models are the standard for oncology, built from progression-free and overall survival curves fitted to trial data. Discrete event simulation is used selectively for conditions with highly individualized patient trajectories that a Markov structure's memoryless assumption would misrepresent. BioNixus selects model architecture based on the clinical evidence available and the disease area's established modeling conventions, not a default template applied regardless of fit.

Local data sourcing is the methodological step that most distinguishes a Saudi-credible cost-effectiveness analysis from an imported one. Clinical event rates and transition probabilities are drawn from Saudi or regional published literature where available, with a documented transferability assessment when a model needs to rely on non-Saudi data. Utility values are sourced from published Arab-population studies where they exist, or generated through primary EQ-5D data collection where a meaningful gap remains. Unit costs draw on NUPCO published pricing, Saudi hospital cost data where accessible, and primary expert elicitation where public cost data is incomplete — a genuinely different exercise from NHS reference costs or US Medicare fee schedules, and one that requires purpose-built data-sourcing effort rather than a substitution exercise on an imported spreadsheet.

Comparator selection has to satisfy two audiences at once: clinical relevance (the therapy Saudi prescribers would actually displace) and consistency with SFDA's reference-pricing framework, since the comparator's price anchors both the cost-effectiveness argument and the pricing procedure the submission also has to clear. A comparator chosen purely for favorable cost-effectiveness optics, without regard to what SFDA's reference-pricing basket or Saudi clinical practice actually uses, weakens the credibility of the entire submission.

Sensitivity and scenario analysis is built around a base case plus stress bands rather than a single point estimate — one-way sensitivity analysis isolating which individual inputs move the ICER most, and scenario analysis stress-testing plausible combinations a skeptical reviewer might construct independently. Discount rates, time horizon, and the extent of probabilistic sensitivity analysis are aligned to what current SFDA guidance specifies at the time of submission — since these technical parameters are the kind of detail that can be updated as the Economic Evaluation Studies Guideline matures, BioNixus confirms current requirements against the live guideline rather than a fixed assumption at the start of every engagement.

Model validation includes an internal adversarial review before external delivery, where BioNixus stakeholders deliberately challenge the model's comparator choice, input provenance, and sensitivity coverage the way an SFDA or NUPCO reviewer would, so weak points are identified and addressed before a sponsor faces the same questions in a live review. Limitation statements are documented explicitly rather than omitted, because a model that acknowledges its own boundaries is more credible to a reviewer than one that implies false precision.

Every cost-effectiveness deliverable ships with an audit-ready methodology appendix — input provenance, sensitivity ranges, comparator justification, and limitation statements documented in a format an SFDA reviewer, a NUPCO tender evaluator, or an internal compliance team can review without requiring the original modeling team to reconstruct the logic after delivery.

Cross-functional readouts should include market access, medical affairs, commercial, and—where relevant—finance representatives in one structured session. When each function receives a differently framed deck, affiliates lose weeks reconciling incompatible narratives before committee or launch decisions.

BioNixus documents recruitment sources, exclusion reason codes, and quota telemetry in audit-ready appendices so medical affairs and compliance reviewers can trace sample integrity without requesting ad hoc forensics after field closes.

For multinational sponsors, harmonized variable dictionaries and coding frameworks let regional roll-ups compare Saudi, UAE, Kuwait, and Egypt cells without forcing identical institutional assumptions that would distort local access realism.

Ethics permissions, hospital data-use agreements, and MOH research authorizations can extend timelines when not mapped during feasibility. Early feasibility sprints surface these gates before recruitment calendars lock and budgets commit.

Common Saudi Arabia cost-effectiveness analysis use cases

Cost-effectiveness analysis demand in Saudi Arabia peaks where SFDA's Full Economic Study tier applies — chronic, oncology, and specialty submissions where comparative clinical value against standard of care is central to the registration, pricing, or reimbursement decision.

• SFDA Full Economic Study registration submissions
• Oncology and specialty-therapy value arguments
• Chronic-disease comparative-effectiveness submissions
• Comparator and reference-pricing justification
• Managed entry agreement design and negotiation support
• NUPCO tender economic-value argument
• International model adaptation for SFDA submission
• GCC portfolio cost-effectiveness harmonization from a Saudi anchor model

Saudi cost-effectiveness analysis engagement timeline

1. Step 1

   Objective and decision-gate lock

   BioNixus confirms which specific gate the analysis needs to clear — SFDA Full Economic Study registration, a NUPCO tender submission, or a managed entry agreement negotiation — and whether the product's profile genuinely triggers the Full Economic Study tier or can be supported by a lighter Partial Economic Study. This stage also maps what Saudi or regionally-validated utility, cost, and epidemiology data already exists versus what requires primary collection or adaptation from an international model, so the proposal reflects a realistic build timeline.

2. Step 2

   Model architecture and comparator selection

   BioNixus selects model structure based on the clinical evidence and disease area, confirms the comparator against both Saudi clinical practice and SFDA's reference-pricing framework, and documents data sourcing strategy for utility values, unit costs, and epidemiological inputs — flagging any Saudi-specific data gaps that require primary collection before the model can be finalized.

3. Step 3

   Model build, sensitivity layering, and internal stress-test

   The base-case model is built, followed by one-way and scenario sensitivity analysis calibrated to the objections an SFDA or NUPCO reviewer is likely to raise. Before external delivery, BioNixus runs an internal adversarial review — deliberately challenging comparator choice, input provenance, and sensitivity coverage — so weak points are addressed while there is still time to strengthen the model.

4. Step 4

   Dossier handover and narrative alignment

   Final deliverables include the model file, a full methodology and limitation appendix, and an executive summary framed for the specific decision-maker audience — SFDA registration reviewer, NUPCO tender evaluator, or internal access and medical affairs stakeholders. BioNixus works with access, medical affairs, and HEOR stakeholders together at handover so the cost-effectiveness narrative aligns with whatever budget impact analysis or market access evidence is being submitted alongside it.

Saudi cost-effectiveness analysis outputs

• Executive summary mapped to one commercial, access, or medical decision
• Stakeholder segmentation with influence and objection themes
• Quantitative sizing or adoption metrics where the objective requires measurement
• Qualitative depth modules for behaviour and pathway questions
• 30/60/90 action plan with owners and evidence gaps flagged
• Audit-ready methodology appendix for internal review or regulator dialogue
• Executable cost-utility (cost-per-QALY) model file with documented input provenance
• Comparator and reference-pricing justification aligned to SFDA's pricing framework
• Sensitivity and scenario tables built around likely SFDA or NUPCO reviewer objections

Executive decision blueprint